ClinicalTrials.gov record
Completed Early Phase 1 Interventional Accepts healthy volunteers

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

ClinicalTrials.gov ID: NCT03426969

Public ClinicalTrials.gov record NCT03426969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis

Study identification

NCT ID
NCT03426969
Recruitment status
Completed
Study type
Interventional
Phase
Early Phase 1
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
3 participants

Conditions and interventions

Interventions

  • Cyclophosphamide Drug
  • Filgrastim Biological
  • Fludarabine Phosphate Drug
  • Hematopoietic Cell Transplantation Procedure
  • Melphalan Drug
  • Mycophenolate Mofetil Drug
  • Tacrolimus Drug
  • Total-Body Irradiation Radiation

Drug · Biological · Procedure + 1 more

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2018
Primary completion
Sep 20, 2020
Completion
Sep 20, 2020
Last update posted
Oct 13, 2020

2018 – 2020

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03426969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2020 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03426969 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →